science
Biomednewsbreaks - Transcode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Updated Phase 1A Data For TTX-MC138 In Advanced Solid Tumors

(MENAFN - Investor Brand Network) TransCode Therapeutics (NASDAQ: RNAZ) reported updated clinical data from its Phase 1a trial of TTX-MC138 in patients with relapsed or refractory, unresectable ...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
ROI & HILM 2027: Verisma Leads Black Book Rankings
Menafn

Edge AI Market Size, Share, Growth, Analysis, Report, 2034
Menafn

Sweden Opens Travel Agency For Introverts
Menafn
APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
Menafn

French Minister Visits ILBS, Boosts Indo-French Research Collaboration
Menafn